Oslo, May 23, 2025 - Induct AS announces that AstraZeneca has decided to
accelerate the initiation of commercial discussions related to the strategic
collaboration with Induct. The first digital meetings will occur before the
summer of 2025, followed by an in-person meeting in England in July.
The purpose of the meetings is to develop a concrete framework for the rollout
of Induct's care pathway for severe asthma in the UK healthcare market. The
discussions will cover subscription-based pricing models and strategy for the
national rollout of the severe asthma program in England. In addition,
AstraZeneca now wishes to expand the collaboration to include other care
pathways where Induct can contribute to increased value for healthcare services
and patients.
"This is a milestone for Induct. That AstraZeneca wants to accelerate the
process is a strong confirmation of the relevance and potential of our solution.
We look forward to the upcoming discussions, and especially to creating value
for both the healthcare system and our shareholders through a strengthened
collaboration," says Synnøve Jacobsen, CEO of Induct.
Chairman of the Board at Induct, Karl-Anders Grønland, comments:
"That these discussions are happening earlier than expected reflects the strong
trust between the parties. We are very pleased that the collaboration is now
entering a new and more concrete phase."
Induct will inform the market of further developments in accordance with
applicable regulations.
For further information, please contact:
Synnøve Jacobsen, CEO
Email: sj@induct.net
Phone: +47 99 41 54 47